Abseamed

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
21-08-2023
Ciri produk Ciri produk (SPC)
21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
03-10-2018

Bahan aktif:

epoetin alfa

Boleh didapati daripada:

Medice Arzneimittel Pütter GmbH Co. KG

Kod ATC:

B03XA01

INN (Nama Antarabangsa):

epoetin alfa

Kumpulan terapeutik:

Antianemic preparations

Kawasan terapeutik:

Anemia; Kidney Failure, Chronic; Cancer

Tanda-tanda terapeutik:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).Abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

Ringkasan produk:

Revision: 22

Status kebenaran:

Authorised

Tarikh kebenaran:

2007-08-27

Risalah maklumat

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ABSEAMED 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 2,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 3,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 4,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 6,000 IU/0.6 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 7,000 IU/0.7 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 8,000 IU/0.8 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 9,000 IU/0.9 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 10,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 20,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 30,000 IU/0.75 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 40,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Abseamed is and what it is used for
2.
What you need to know before you use Abseamed
3.
How to use Abseamed
4.
Possible side effects
5.
How to store Abseamed
6.
Contents of the pack and other information
1.
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
Abseamed contains the active substance epoetin alfa, a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoe
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled
syringe
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled
syringe
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled
syringe
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled
syringe
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled
syringe
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU)
corresponding to 8.4 micrograms
epoetin alfa. *
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU)
corresponding to 16.8 micrograms
epoetin alfa. *
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*
corresponding to 84.0 micrograms per mL
A pre-filled syringe of 0.3 mL contains 3,000 international units (IU)
corresponding
to 25.2 micrograms epoetin alfa. *
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*

                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 21-08-2023
Ciri produk Ciri produk Bulgaria 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 03-10-2018
Risalah maklumat Risalah maklumat Sepanyol 21-08-2023
Ciri produk Ciri produk Sepanyol 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 03-10-2018
Risalah maklumat Risalah maklumat Czech 21-08-2023
Ciri produk Ciri produk Czech 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 03-10-2018
Risalah maklumat Risalah maklumat Denmark 21-08-2023
Ciri produk Ciri produk Denmark 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 03-10-2018
Risalah maklumat Risalah maklumat Jerman 21-08-2023
Ciri produk Ciri produk Jerman 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 03-10-2018
Risalah maklumat Risalah maklumat Estonia 21-08-2023
Ciri produk Ciri produk Estonia 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 03-10-2018
Risalah maklumat Risalah maklumat Greek 21-08-2023
Ciri produk Ciri produk Greek 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 03-10-2018
Risalah maklumat Risalah maklumat Perancis 21-08-2023
Ciri produk Ciri produk Perancis 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 03-10-2018
Risalah maklumat Risalah maklumat Itali 21-08-2023
Ciri produk Ciri produk Itali 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 03-10-2018
Risalah maklumat Risalah maklumat Latvia 21-08-2023
Ciri produk Ciri produk Latvia 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 03-10-2018
Risalah maklumat Risalah maklumat Lithuania 21-08-2023
Ciri produk Ciri produk Lithuania 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 03-10-2018
Risalah maklumat Risalah maklumat Hungary 21-08-2023
Ciri produk Ciri produk Hungary 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 03-10-2018
Risalah maklumat Risalah maklumat Malta 21-08-2023
Ciri produk Ciri produk Malta 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 03-10-2018
Risalah maklumat Risalah maklumat Belanda 21-08-2023
Ciri produk Ciri produk Belanda 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 03-10-2018
Risalah maklumat Risalah maklumat Poland 21-08-2023
Ciri produk Ciri produk Poland 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 03-10-2018
Risalah maklumat Risalah maklumat Portugis 21-08-2023
Ciri produk Ciri produk Portugis 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 03-10-2018
Risalah maklumat Risalah maklumat Romania 21-08-2023
Ciri produk Ciri produk Romania 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 03-10-2018
Risalah maklumat Risalah maklumat Slovak 21-08-2023
Ciri produk Ciri produk Slovak 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 03-10-2018
Risalah maklumat Risalah maklumat Slovenia 21-08-2023
Ciri produk Ciri produk Slovenia 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 03-10-2018
Risalah maklumat Risalah maklumat Finland 21-08-2023
Ciri produk Ciri produk Finland 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 03-10-2018
Risalah maklumat Risalah maklumat Sweden 21-08-2023
Ciri produk Ciri produk Sweden 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 03-10-2018
Risalah maklumat Risalah maklumat Norway 21-08-2023
Ciri produk Ciri produk Norway 21-08-2023
Risalah maklumat Risalah maklumat Iceland 21-08-2023
Ciri produk Ciri produk Iceland 21-08-2023
Risalah maklumat Risalah maklumat Croat 21-08-2023
Ciri produk Ciri produk Croat 21-08-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 03-10-2018

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen